Pharmaceutical Stocks
Big Pharma and specialty drug companies. Patent-protected revenue streams, massive R&D pipelines, and global distribution.
176 stocks
Updated Nov 9, 2026
$3.88T
Total Market Cap
33.9
Avg P/E Ratio
3.75%
Avg Dividend Yield
+1.96%
Avg Daily Change
Pharmaceutical stocks represent companies that discover, develop, manufacture, and market prescription drugs. The pharma sector is one of the most profitable in the market, with leading companies generating billions in annual revenue from blockbuster drugs that treat widespread conditions.
The industry is dominated by large-cap companies like Pfizer, Eli Lilly, Johnson & Johnson, Merck, and AbbVie, each with diversified drug portfolios and extensive R&D pipelines. Revenue is driven by patent-protected branded drugs that command premium pricing, though companies face revenue cliffs when patents expire and generic competitors enter.
Recent growth catalysts include the GLP-1 obesity drug revolution led by Eli Lilly and Novo Nordisk, advances in oncology immunotherapy, and expanding use of mRNA technology beyond vaccines. This list tracks pharmaceutical companies with prices, P/E ratios, dividend yields, and market caps updated daily.
| # | Symbol | Name | Price | Change % | P/E | Market Cap |
|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Co. | $1,403.15 | +3.63% | 46.6 | 1.28T |
| 2 | RDY | Dr. Reddy's Laboratories | $14.98 | +0.47% | 18.2 | 1.01T |
| 3 | JNJ | Johnson & Johnson | $281.29 | +1.84% | 40.8 | 656.45B |
| 4 | MRK | Merck & Co. Inc. | $147.81 | +0.74% | 147.8 | 362.53B |
| 5 | PFE | Pfizer Inc. | $29.47 | +0.27% | 41.4 | 167.12B |
| 6 | BMY | Bristol-Myers Squibb Co | $62.14 | -1.57% | 13.8 | 127.96B |
| 7 | RPRX | Royalty Pharma Plc- Cl A | $67.30 | -0.40% | 47.5 | 38.68B |
| 8 | ZTS | Zoetis Inc | $82.35 | +3.72% | 12.8 | 33.59B |
| 9 | VTRS | Viatris Inc | $20.50 | +2.96% | — | 22.38B |
| 10 | JAZZ | Jazz Pharmaceuticals Plc | $243.11 | +3.56% | 73.2 | 15.07B |
| 11 | ELAN | Elanco Animal Health Inc | $26.91 | +4.55% | — | 12.97B |
| 12 | CRNX | Crinetics Pharmaceuticals In | $84.95 | +0.13% | — | 9.01B |
| 13 | CORT | Corcept Therapeutics Inc | $75.52 | +3.78% | 142.1 | 7.84B |
| 14 | AMRX | Amneal Pharmaceuticals Inc | $21.28 | +5.66% | 45.1 | 7.10B |
| 15 | AXSM | Axsome Therapeutics Inc | $133.26 | +0.67% | — | 6.99B |
| 16 | TERN | Terns Pharmaceuticals Inc | $52.95 | +0.00% | — | 6.12B |
| 17 | LGND | Ligand Pharmaceuticals | $313.58 | +2.41% | 30.3 | 5.98B |
| 18 | SUPN | Supernus Pharmaceuticals Inc | $27.62 | +5.58% | 16.2 | 5.55B |
| 19 | EWTX | Edgewise Therapeutics Inc | $47.41 | +5.26% | — | 4.89B |
| 20 | DFTX | Definium Therapeutics Inc | $35.12 | +5.56% | — | 4.43B |
| 21 | BHC | Bausch Health Cos Inc | $8.48 | +3.67% | — | 4.37B |
| 22 | INDV | Indivior Pharmaceuticals Inc | $26.16 | -2.17% | 12.1 | 4.28B |
| 23 | LQDA | Liquidia Corp | $47.86 | +7.79% | 28.7 | 3.97B |
| 24 | AMLX | Amylyx Pharmaceuticals Inc | $29.50 | +6.81% | — | 3.70B |
| 25 | OGN | Organon & Co | $13.87 | +0.00% | 17.4 | 3.64B |
| 26 | ELVN | Enliven Therapeutics Inc | $51.67 | +4.53% | — | 3.57B |
| 27 | TARS | Tarsus Pharmaceuticals Inc | $69.64 | +1.52% | — | 3.38B |
| 28 | ATAI | Ataibeckley Inc | $7.35 | +0.82% | — | 2.73B |
| 29 | XERS | Xeris Biopharma Holdings Inc | $15.20 | +16.21% | — | 2.68B |
| 30 | RGC | Regencell Bioscience Holding | $5.67 | +7.59% | — | 2.61B |
| 31 | PHVS | Pharvaris Nv | $34.37 | -0.06% | — | 2.41B |
| 32 | MBX | Mbx Biosciences Inc | $54.53 | +6.19% | — | 2.33B |
| 33 | SEPN | Septerna Inc | $48.85 | +3.17% | — | 2.21B |
| 34 | PRGO | Perrigo Co Plc | $16.82 | +6.12% | — | 2.16B |
| 35 | AVDL | Avadel Pharmaceuticals | $21.64 | +0.05% | — | 2.12B |
| 36 | PBH | Prestige Consumer Healthcare | $43.34 | +0.84% | 12.0 | 2.06B |
| 37 | TRVI | Trevi Therapeutics Inc | $14.33 | +11.87% | — | 1.99B |
| 38 | HRMY | Harmony Biosciences Holdings | $33.78 | +2.02% | 10.6 | 1.93B |
| 39 | CRON | Cronos Group Inc | $3.61 | -2.96% | 18.5 | 1.82B |
| 40 | MAZE | Maze Therapeutics Inc | $35.26 | +3.13% | — | 1.81B |
| 41 | ETON | Eton Pharmaceuticals Inc | $56.46 | +19.75% | 128.5 | 1.63B |
| 42 | ANIP | Ani Pharmaceuticals Inc | $67.48 | +0.10% | 14.8 | 1.60B |
| 43 | NUVB | Nuvation Bio Inc | $4.16 | -0.72% | — | 1.48B |
| 44 | PCRX | Pacira Biosciences Inc | $36.43 | +0.03% | 99.2 | 1.45B |
| 45 | PAHC | Phibro Animal Health Corp-A | $34.64 | +5.10% | 14.4 | 1.44B |
| 46 | OCUL | Ocular Therapeutix Inc | $6.60 | +2.57% | — | 1.41B |
| 47 | INVA | Innoviva Inc | $18.91 | -0.99% | 3.9 | 1.41B |
| 48 | LBRX | Lb Pharmaceuticals Inc | $42.01 | +10.29% | — | 1.28B |
| 49 | GHRS | Gh Research Plc | $18.61 | +0.92% | — | 1.28B |
| 50 | NKTR | Nektar Therapeutics | $37.26 | +3.07% | — | 1.25B |
| 51 | OMER | Omeros Corp | $16.92 | -0.88% | 9.9 | 1.24B |
| 52 | AMPH | Amphastar Pharmaceuticals In | $28.49 | +3.00% | 15.0 | 1.18B |
| 53 | RAPP | Rapport Therapeutics Inc | $24.44 | +3.04% | — | 1.14B |
| 54 | VTYX | Ventyx Biosciences Inc | $14.00 | +0.14% | — | 1.00B |
| 55 | HROW | Harrow Inc | $27.53 | +2.38% | — | 1.00B |
| 56 | TBPH | Theravance Biopharma Inc | $17.03 | +0.00% | 16.4 | 884.18M |
| 57 | ANRO | Alto Neuroscience Inc | $25.16 | +15.04% | — | 858.22M |
| 58 | ESPR | Esperion Therapeutics Inc | $3.18 | -0.31% | — | 819.46M |
| 59 | COLL | Collegium Pharmaceutical Inc | $24.21 | -3.78% | 16.7 | 799.89M |
| 60 | ALMS | Alumis Inc | $6.48 | +7.46% | — | 780.95M |
| 61 | LXRX | Lexicon Pharmaceuticals Inc | $1.83 | +13.66% | — | 716.38M |
| 62 | ZVRA | Zevra Therapeutics Inc | $11.59 | +10.07% | 11.9 | 694.64M |
| 63 | WVE | Wave Life Sciences Ltd | $3.52 | +4.61% | — | 661.25M |
| 64 | CRMD | Cormedix Inc | $5.32 | +1.72% | 3.2 | 595.49M |
| 65 | ACRS | Aclaris Therapeutics Inc | $3.90 | +8.03% | — | 591.27M |
| 66 | ACB | Aurora Cannabis Inc | $5.24 | +0.96% | — | 480.59M |
| 67 | OCS | Oculis Holding Ag | $7.85 | +4.81% | — | 462.37M |
| 68 | AQST | Aquestive Therapeutics Inc | $3.61 | -1.37% | — | 451.85M |
| 69 | EOLS | Evolus Inc | $6.81 | +0.15% | — | 451.45M |
| 70 | ARVN | Arvinas Inc | $6.41 | -2.14% | 46.1 | 428.27M |
| 71 | RLMD | Relmada Therapeutics Inc | $3.90 | +3.45% | — | 422.95M |
| 72 | PHAT | Phathom Pharmaceuticals Inc | $5.25 | +3.35% | — | 421.50M |
| 73 | TLRY | Tilray Brands Inc | $2.92 | +3.91% | — | 421.19M |
| 74 | CGC | Canopy Growth Corp | $0.65 | -3.58% | — | 401.93M |
| 75 | CTNM | Contineum Therapeutics Inc-A | $9.52 | +8.06% | — | 352.54M |
| 76 | HITI | High Tide Inc | $2.63 | +0.00% | — | 349.44M |
| 77 | AVIR | Atea Pharmaceuticals Inc | $4.36 | +1.16% | — | 345.68M |
| 78 | SNDL | Sndl Inc | $1.42 | +2.54% | — | 344.30M |
| 79 | TTRX | Turn Therapeutics Inc | $9.48 | +6.04% | — | 299.22M |
| 80 | FULC | Fulcrum Therapeutics Inc | $3.70 | +0.54% | — | 283.83M |
| 81 | BIOA | Bioage Labs Inc | $5.34 | -3.61% | — | 254.27M |
| 82 | NGEN | Nervgen Pharma Corp | $1.33 | +0.76% | — | 226.72M |
| 83 | SIGA | Siga Technologies Inc | $3.10 | +4.38% | — | 216.63M |
| 84 | SLGL | Sol-Gel Technologies Ltd | $61.01 | -3.17% | — | 199.71M |
| 85 | OGI | Organigram Global Inc | $0.88 | -5.72% | 2.2 | 188.95M |
| 86 | CRDL | Cardiol Therapeutics Inc-A | $0.99 | -0.50% | — | 173.75M |
| 87 | MDWD | Mediwound Ltd | $14.25 | +6.90% | — | 172.09M |
| 88 | ORMP | Oramed Pharmaceuticals Inc | $3.86 | -0.77% | 0.9 | 161.81M |
| 89 | ASRT | Assertio Holdings Inc | $23.50 | +0.09% | — | 151.86M |
| 90 | ANTX | An2 Therapeutics Inc | $4.00 | +1.14% | — | 150.94M |
| 91 | INCR | Intercure Ltd | $3.44 | -0.86% | — | 141.32M |
| 92 | DERM | Journey Medical Corp | $4.47 | +3.95% | — | 126.16M |
| 93 | PYPD | Polypid Ltd | $6.14 | +8.29% | — | 122.32M |
| 94 | SAVA | Cassava Sciences Inc | $0.45 | +0.38% | — | 114.97M |
| 95 | BGM | Bgm Group Ltd | $8.63 | +4.61% | — | 110.17M |
| 96 | LENZ | Lenz Therapeutics Inc | $3.52 | +16.94% | — | 109.97M |
| 97 | NRXP | Nrx Pharmaceuticals Inc | $2.38 | +4.85% | — | 101.75M |
| 98 | VYNE | Vyne Therapeutics Inc | $13.69 | -8.18% | — | 93.50M |
| 99 | NTHI | Neonc Technologies Holdings | $3.65 | +4.58% | — | 92.18M |
| 100 | NMRA | Neumora Therapeutics Inc | $0.50 | +3.35% | — | 91.51M |
Related ETFs
Exchange-traded funds that provide diversified exposure to the pharmaceutical stocks sector.
IHE
iShares
0.40% ER
iShares U.S. Pharmaceuticals ETF
Pure pharmaceutical exposure. Focuses on drug manufacturers excluding biotech and healthcare equipment.
XLV
SPDR
0.09% ER
Health Care Select Sector SPDR Fund
Broader healthcare ETF with major pharma companies as top holdings alongside biotech and medical devices.
PPH
VanEck
0.36% ER
VanEck Pharmaceutical ETF
Tracks large-cap pharmaceutical companies globally. Includes U.S. and international big pharma names.
Frequently Asked Questions
What are pharma stocks?
Pharma stocks are shares in companies that develop and sell prescription medications. Major pharma companies include Eli Lilly (LLY), Pfizer (PFE), Johnson & Johnson (JNJ), Merck (MRK), and AbbVie (ABBV). These companies typically have large portfolios of approved drugs, extensive R&D pipelines, global distribution networks, and sales forces. The sector also includes specialty pharma companies focused on niche therapeutic areas.
Are pharma stocks a good investment?
Pharma stocks offer a combination of defensive earnings, dividends, and growth potential. Healthcare spending is non-discretionary, providing earnings stability. Major pharma companies pay reliable dividends with yields of 2-4%. Growth comes from new drug approvals and expanded indications. However, risks include patent expirations, drug pricing legislation, and clinical trial failures. The sector is suitable for both income and growth investors depending on company selection.
What are GLP-1 drugs and why do they matter?
GLP-1 receptor agonists are a class of drugs originally developed for diabetes that have shown remarkable effectiveness for weight loss. Eli Lilly's Mounjaro/Zepbound and Novo Nordisk's Ozempic/Wegovy have created a potential $100+ billion market. These drugs have made Eli Lilly one of the most valuable companies in the world. GLP-1s are also showing promise for cardiovascular disease, liver disease, and sleep apnea, potentially expanding the market further.
Do pharma stocks pay dividends?
Yes, most large pharma companies are reliable dividend payers. Johnson & Johnson is a Dividend King with 60+ years of consecutive increases. AbbVie, Pfizer, and Merck all offer yields above 3%. Pharma companies generate substantial free cash flow from patent-protected drugs, supporting both dividends and share buybacks. The combination of moderate yield and consistent growth makes pharma dividends attractive for income portfolios.
What is a patent cliff?
A patent cliff occurs when a blockbuster drug loses patent protection, allowing generic manufacturers to sell competing versions at much lower prices. Revenue for the branded drug typically drops 70-90% within a few years. This is the biggest risk for pharma investors. Companies must continually replenish their portfolios with new drugs through R&D and acquisitions. Major upcoming patent cliffs include AbbVie's Humira (already facing biosimilars) and several oncology drugs.
What is the difference between pharma and biotech?
Pharma companies primarily develop chemical-based drugs (small molecules) and are typically large, profitable, and dividend-paying. Biotech companies use biological processes to develop therapies and are often smaller, pre-profit, and more volatile. In practice, the distinction has blurred — large pharma companies now develop biological drugs and frequently acquire biotechs to access innovative pipelines. Pharma stocks generally offer more stability while biotech offers higher growth potential with more risk.
How does drug pricing regulation affect pharma stocks?
Drug pricing is a significant political and regulatory risk. The Inflation Reduction Act allows Medicare to negotiate prices on certain drugs for the first time, which will reduce revenue on affected medications. Additional pricing reforms could further impact profitability. However, the impact is often less severe than feared — pharma companies can offset pricing pressure through volume growth, new launches, and expanded indications. International markets already have price controls.
What are the biggest pharma stocks by market cap?
Eli Lilly (LLY) has become the most valuable pharma company, driven by its GLP-1 obesity and diabetes franchise. Johnson & Johnson (JNJ) is a diversified healthcare giant with pharma, medical devices, and consumer health divisions. Merck (MRK) leads in oncology with Keytruda, one of the world's best-selling drugs. AbbVie (ABBV) has strong immunology and aesthetics portfolios. Pfizer rounds out the top tier with its broad therapeutic coverage.
More Stock Lists
🧬
Biotech Stocks
Biotechnology companies developing breakthrough drugs, gene therapies, and medical innovations. Binary outcomes with blockbuster upside potential.
→
🩺
Healthcare & Biotech Stocks
Pharma giants, biotech innovators, and healthcare providers. Defensive plays with blockbuster drug upside.
→
💸
Best Dividend Stocks
Quality meets income: dividend stocks yielding 2%+ with sustainable payout ratios under 100%. Large caps that pay you to hold.
→
🎖
Blue Chip Stocks
The market's most established names: large-cap companies with dividends, proven earnings, and decades of track record. Portfolio anchors.
→
💰
Highest Revenue Companies
The world's largest businesses by annual revenue. These companies move the real economy — energy, retail, tech, and finance.
→
★
Highest Profit Margins
Cash machines: companies turning over 25% of revenue into net profit. A sign of pricing power, brand moats, and operational efficiency.
→